Characteristics Based on Molecular Subtypes in Diffuse Large B-Cell Lymphoma Cases

Authors

  • Norsikawaty Haya Department of Pathology Anatomy, Hasanuddin University, Makassar, Indonesia
  • Husni Cangara Department of Pathology Anatomy, Hasanuddin University, Makassar, Indonesia
  • Upik A. Miskad Department of Pathology Anatomy, Hasanuddin University, Makassar, Indonesia
  • Gunawan Arsyadi Department of Pathology Anatomy, Hasanuddin University, Makassar, Indonesia
  • Ni Ketut Sungowati Department of Pathology Anatomy, Hasanuddin University, Makassar, Indonesia
  • Andi A. Zainuddin Department of Public Health, Hasanuddin University, Makassar, Indonesia
  • Dzul Ikram Department of Pathology Anatomy, Hasanuddin University, Makassar, Indonesia

Keywords:

GCB, ABC, Non-GCB, DLBCL, Makassar

Abstract

Diffuse B-cell origin large cell lymphoma (DLBCL) is a type of non-Hodgkin's malignant lymphoma most commonly found in adults. Based on the gene or molecular expression profile, DLBCL can be divided into GCB (Germinal Center B-Cell-Like) and ABC / Non-GCB (Activated B-Cell-Like). However, identification of this grouping is still rarely done in Indonesia, especially Makassar City. This study aims to determine the characteristics of DLBCL cases based on molecular examination. This study used a sample of 44 cases of paraffin block for DLBCL patients from 2017 to 2019, then categorized using the Hans algorithm. Of the 44 cases, the number of GCB was 8 cases (18.2%) and ABC / Non-GCB 36 cases (81.8%). The incidence of female sex was slightly lower (47.7%) than in men (52.3%) with the most frequent location being nodal with 36 cases (81.8%) and extranodal as many as 8 cases (18.2%) . Meanwhile, age was found more frequently in patients with age <60 years (32 cases, 72.7%) than those aged> 60 years (12 cases, 27.3%) with a mean age of 52.57 years. The results showed that the ABC / Non-GCB type DLBCL was more common than the GCB type in patients in Makassar city.

References

. R. L. Siegel and K. D. Miller, “Cancer Statistics , 2019,” vol. 69, no. 1, pp. 7–34, 2019.

. S. W. P. RI, “No Titleآبهای زیرزمینی,” آب و خاک, 2017.

. Y. Snak, Indrawati, K. Widayati, N. Arfian, and N. Anggorowati, “Molecular subtypes, apoptosis and proliferation status in Indonesian diffuse large B-cell lymphoma cases,” Asian Pacific J. Cancer Prev., vol. 19, no. 1, pp. 185–191, 2018.

. S. Mareschal, H. Lanic, P. Ruminy, C. Bastard, H. Tilly, and F. Jardin, “The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age,” Haematologica, vol. 96, no. 12, pp. 1888–1890, 2011.

. Y. Chen et al., “Diffuse large B-cell lymphoma in Chinese patients,” Am. J. Clin. Pathol., vol. 133, no. 2, pp. 305–313, 2010.

. E. Shiozawa, T. Yamochi-Onizuka, M. Takimoto, and H. Ota, “The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries,” Leuk. Res., vol. 31, no. 11, pp. 1579–1583, 2007.

. J. Sun et al., “Distribution of lymphoid neoplasms in China: Analysis of 4,638 cases according to the World Health Organization Classification,” Am. J. Clin. Pathol., vol. 138, no. 3, pp. 429–434, 2012.

. S. J. Lee et al., “Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer’s ring: Nationwide Korean study,” Korean J. Intern. Med., vol. 29, no. 3, pp. 352–360, 2014.

. S. Dayang Sharyati Datu Abdul, S.-H. Teoh, S.-C. Peh, and S.-C. Cheah, “Retrospective Lymphoma Study from Malaysia Private Hospital,” Int. J. Cancer Clin. Res., vol. 7, no. 4, pp. 1–8, 2020.

. A. Smith, E. Roman, D. Howell, R. Jones, R. Patmore, and A. Jack, “The haematological malignancy research network (HMRN): A new information strategy for population based epidemiology and health service research,” Br. J. Haematol., vol. 148, no. 5, pp. 739–753, 2010.

. et al., “Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China,” Chinese J. Cancer Res., vol. 31, no. 1, pp. 152–161, 2019.

. C. Chemotherapy, P. Rituximab, C. With, C. Aloneelderly, P. With, and D. L. Lymphoma, “C H O P P LUS RIT UXIMAB VS . CHOP AL ONE IN ELD ERLY PATIENTS WITH D IFFUS E L A R GE-B - CELL LYMPH OM A CHOP CHEMOTHERAPY PLUS RITUXIMAB COMPARED WITH CHOP ALONE IN ELDERLY PATIENTS WITH DIFFUSE LARGE-B-CELL LYMPHOMA,” vol. 346, no. 4, pp. 235–242, 2002.

. J. Y. Kwak, “Treatment of diffuse large B cell lymphoma,” Korean J. Intern. Med., vol. 27, no. 4, pp. 369–377, 2012.

. W. W. L. Choi et al., “A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy,” Clin. Cancer Res., vol. 15, no. 17, pp. 5494–5502, 2009.

. R. Coutinho et al., “Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large b-cell lymphoma: Implications for therapeutic strategies,” Clin. Cancer Res., vol. 19, no. 24, pp. 6686–6695, 2013.

. Y. Liu and S. K. Barta, “Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment,” Am. J. Hematol., vol. 94, no. 5, pp. 604–616, 2019.

Downloads

Published

2021-01-15

How to Cite

Haya, N. ., Cangara, H. ., A. Miskad, U. ., Arsyadi, G. ., Sungowati, N. K. ., A. Zainuddin, A. ., & Ikram, D. . (2021). Characteristics Based on Molecular Subtypes in Diffuse Large B-Cell Lymphoma Cases. International Journal of Sciences: Basic and Applied Research (IJSBAR), 55(1), 183–189. Retrieved from https://gssrr.org/index.php/JournalOfBasicAndApplied/article/view/12220

Issue

Vol. 55 No. 1 (2021)

Section

Articles

License

Authors who submit papers with this journal agree to the following terms.